Soligenix Inc. (NASDAQ: SNGX) is developing a novel therapeutic approach for cutaneous T-cell lymphoma (CTCL), a cancer that clinicians recognize as one of the most difficult to diagnose accurately in its early stages. The company's HyBryte therapy, also known as synthetic hypericin, represents a potential advancement in addressing critical gaps in rare disease treatment.
HyBryte is a visible light-activated photodynamic therapy designed specifically for early-stage CTCL. Unlike traditional ultraviolet-based phototherapies that carry long-term safety risks with cumulative exposure, HyBryte is activated by visible light in the red-yellow spectrum. This mechanism allows for targeted treatment of malignant T-cells in the skin while minimizing damage to surrounding healthy tissue.
Clinical data reported by Soligenix indicate that HyBryte has demonstrated statistically significant efficacy in reducing CTCL lesions in patients with early-stage disease. The company's Specialized BioTherapeutics business segment is developing and moving toward potential commercialization of HyBryte, with regulatory approvals being sought worldwide following successful completion of the second Phase 3 study.
Soligenix is a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need. The company's development programs also include expansion of synthetic hypericin into psoriasis, as well as its first-in-class innate defense regulator technology, dusquetide, for the treatment of inflammatory diseases including oral mucositis in head and neck cancer.
The company's Public Health Solutions business segment includes development programs for RiVax, its ricin toxin vaccine candidate, and vaccine programs targeting filoviruses such as Marburg and Ebola. This segment also includes CiVax, the company's vaccine candidate for the prevention of COVID-19 caused by SARS-CoV-2. These vaccine programs incorporate Soligenix's proprietary heat stabilization platform technology known as ThermoVax.
To date, the Public Health Solutions business segment has been supported with government grants and contract funding from the National Institute of Allergy and Infectious Diseases (NIAID), the Defense Threat Reduction Agency (DTRA), and the Biomedical Advanced Research and Development Authority (BARDA). For further information about the company's developments, visit https://www.Soligenix.com.
The development of HyBryte addresses a significant medical need in oncology, particularly for patients with early-stage CTCL who currently face limited treatment options with better safety profiles. The visible light activation mechanism represents a technological advancement that could reduce long-term treatment risks compared to existing ultraviolet therapies. As Soligenix moves toward potential commercialization, this therapy could provide clinicians with a more targeted approach to managing this challenging form of lymphoma.
The latest news and updates relating to Soligenix are available in the company's newsroom at https://ibn.fm/SNGX. NetworkNewsWire, which published information about Soligenix's developments, is a specialized communications platform with a focus on financial news and content distribution. It is one of 75+ brands within the Dynamic Brand Portfolio at IBN that delivers various corporate communications solutions. For more information about NetworkNewsWire, visit https://www.NetworkNewsWire.com.
